Origanum

by | Mar 21, 2018 | Origanum

How Can We Help?
You are here:
< Back

TC-1827 is an orally active, selective agonist of the α4β2 nicotinic receptors. Administration of TC-1827 improved memory and learning in a variety of rodents and increased long-term potentiation in hippocampal slices. In addition, the compound was without significant cardiovascular side effects, except for a small, transient rise in arterial blood pressure. The pro-cognitive effects of TC-1827 last much longer than the short half life (0.2 - 1.0 hours) would suggest.[1]

References

  1. ^ Bohme, Georg Andrees (May 2004). "In vitro and in vivo characterization of TC-1827, a novel brain α4β2 nicotinic receptor agonist with pro-cognitive activity". Drug Development Research. 62 (1): 26–40. doi:10.1002/ddr.10352. S2CID 86072368.
Categories
Table of Contents